Search

Your search keyword '"Bruijnzeel-Koomen, C. A. F. M."' showing total 307 results
Start Over Author "Bruijnzeel-Koomen, C. A. F. M."
307 results on '"Bruijnzeel-Koomen, C. A. F. M."'

1. Effectiveness of alpine climate treatment for children with difficult to treat atopic dermatitis: Results of a pragmatic randomized controlled trial (DAVOS trial)

Author

Fieten, K. B., Schappin, R., Zijlstra, W. T., Figee, L., Beutler, J., Raymakers, F., van Os‐Medendorp, H., Stellato, R., Vandewall, M., Winkelhof, J., Uniken Venema, M., Bruijnzeel‐Koomen, C. A. F. M., Rijssenbeek‐Nouwens, L., van der Ent, C. K., van Hoffen, E., Meijer, Y., and Pasmans, S. G. M. A.

Published
2018
Full Text
View/download PDF

44. Effectiveness of alpine climate treatment for children with difficult to treat atopic dermatitis: Results of a pragmatic randomized controlled trial (DAVOS trial)

Author

Fieten, K. B., primary, Schappin, R., additional, Zijlstra, W. T., additional, Figee, L., additional, Beutler, J., additional, Raymakers, F., additional, van Os-Medendorp, H., additional, Stellato, R., additional, Vandewall, M., additional, Winkelhof, J., additional, Uniken Venema, M., additional, Bruijnzeel-Koomen, C. A. F. M., additional, Rijssenbeek-Nouwens, L., additional, van der Ent, C. K., additional, van Hoffen, E., additional, Meijer, Y., additional, and Pasmans, S. G. M. A., additional

Published
2017
Full Text
View/download PDF

45. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis

Author

Verburg, M., Oldhoff, J. M., Klemans, R. J. B., Lahey-De Boer, A., Bruin-Weller, M. S., Röckmann, H., Sanders, C., Bruijnzeel-Koomen, C. A. F. M., Suzanne G.M.A. Pasmans, Knulst, A. C., Dermatology, and Immunology

Abstract

BACKGROUND: Patients with mastocytosis and wasp venom allergy (WA) may benefit from venom immunotherapy (VIT). However, fatal insect sting reactions have been described in mastocytosis patients despite previous immunotherapy. We investigated the safety and efficacy of (rush) VIT in patients with mastocytosis and WA. OBJECTIVE: To investigate the safety and efficacy of (rush) VIT in patients with mastocytosis and WA. METHODS: We describe nine patients with cutaneous mastocytosis and WA who received VIT. Cutaneous mastocytosis was confirmed by histopathology and systemic mastocytosis was diagnosed according to World Health Organization criteria. VIT was given according to a rush protocol. Given the difference in safety and efficacy of VIT in patients with WA and honeybee venom allergy, we reviewed the literature for VIT with the focus on WA patients with mastocytosis and addressed the difference between patients with cutaneous versus systemic mastocytosis. RESULTS: Nine patients had WA and mastocytosis, of whom six had cutaneous mastocytosis, two combined cutaneous and systemic mastocytosis and one systemic mastocytosis. All patients received rush IT with wasp venom. Most patients had only mild local side effects, with no systemic side effects during the course of VIT. One patient had a systemic reaction upon injection on one occasion, during the updosing phase, with dyspnoea and hypotension, but responded well to treatment. Immunotherapy was continued after temporary dose adjustment without problems. Two patients with a previous anaphylactic reaction were re-stung, without any systemic effects. CONCLUSIONS: VIT is safe in cutaneous mastocytosis patients with WA, while caution has to be made in case of systemic mastocytosis. VIT was effective in the patients who were re-stung.

Published
2015

46. Increased liver enzyme levels during azathioprine treatment : Beware of concomitant use of proton pump inhibitors

Author

Van Der Schaft, J., Van Schaik, R. H N, Van Den Broek, M. P H, Bruijnzeel-Koomen, C. A F M, and De Bruin-Weller, M. S.

Subjects
DOUBLE-BLIND, Letter, SEVERE ATOPIC ECZEMA, TRIAL, Case Reports
Abstract

Azathioprine (AZA) is a purine antagonist, which is frequently used off label in chronic inflammatory skin diseases. Genetic polymorphisms in thiopurine S-methyltransferase (TPMT) influence the metabolism of AZA. A reduced enzymatic activity of TMPT is associated with increased 6-thioguaninie nucleotide (6-TGN) levels which may cause severe leukopenia. High TPMT activity is associated with increased 6-methylmercaptopurine (6-MMP) levels (toxic 6-MMP >5700 pmol/8x10(8) RBCs), which is associated with liver toxicity.(1) Alanine transaminase (ALT) >3 upper limits of normal has been identified as a sensitive, but not necessarily specific signal of liver toxicity.(2) In daily practice AZA is often started with a test dose of 50 mg/day for 1-2 weeks. If laboratory tests show no abnormalities, the dose is increased to up to 150-200 mg/day. This article is protected by copyright. All rights reserved.

Published
2015

49. Richtlijn constitutioneel eczeem (herz. versie) [Online]

Author

Bruijnzeel-Koomen, C. A. F. M., Spuls, P. I., de Bruin-Weller, M. S., Pasmans, S. G. M. A., Oranje, A., Tupker, R., Schuttelaar, M. L. A., Rustemeyer, T., de Vries, C. J. H., van Os-Medendorp, H., Zijlstra, W., Oude Elberink, J. N. G., Breukels, M. A., Jungbauer, F., Kouwenhoven, W. N. M., van Everdingen, J. E. E., Amsterdam institute for Infection and Immunity, Amsterdam Public Health, and Dermatology

Published
2014

50. Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands.

Author

Garritsen, F. M., van den Heuvel, J. M., Bruijnzeel-Koomen, C. A. F. M., Maitland-van der Zee, A. H., van den Broek, M. P. H., and de Bruin-Weller, M. S.

Subjects
IMMUNOSUPPRESSIVE agents, ATOPIC dermatitis, SKIN diseases, PHARMACY databases, CYCLOSPORINE
Abstract

Background Although atopic dermatitis (AD) is a very common skin disease, data on the percentage of patients with really difficult-to-treat AD are scarce. From socio-economic perspective, it is important to have more insight into these numbers, as new very effective, but expensive, treatment options will be available in the near future for difficult-to-treat AD. Estimating the number of patients with AD using oral immunosuppressive drugs can give an impression of the percentage of difficult-to-treat patients in the total AD population. Objective To give an overview of the use of oral immunosuppressive drugs in patients with AD in the Netherlands. Methods Prescription data of oral immunosuppressive drugs in the Netherlands were extracted from a pharmaceutical database (NControl) containing data of 557 million prescriptions and 7.2 million patients. An algorithm, based on the WHO Anatomical Therapeutic Chemical (ATC) codes, was used to identify patients with AD. The prescription of oral immunosuppressive drugs in patients with AD between 1 January 2012 and 1 January 2017 was evaluated. Results Based on the algorithm, 65 943 patients with AD were selected. 943 patients with AD (1.4%) used cyclosporine A, methotrexate, azathioprine or mycophenolic acid. Methotrexate was most commonly used, followed by azathioprine and cyclosporine A. A switch in medication was rarely seen. In the evaluation period, a decrease in the prescription of cyclosporine A was seen, together with an increase in the prescription of methotrexate. In 31% of the patients who stopped treatment, the discontinuation took place within the first months of treatment. Conclusion In this study population, 1.4% of the patients with AD used oral immunosuppressive drugs for their eczema in a 5-year period. Methotrexate was the most commonly used systemic drug in the Netherlands for the treatment of AD. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results